Why The FDA Panel's Nod To Sandoz's Filgrastim (Zarzio) Is Good News For Patients
The implications extend beyond cancer drugs. Biosimilars have the potential to significantly reduce the costs of modern health care for people with all kinds of illness
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Elaine Schattner Source Type: news
More News: Cancer | Cancer & Oncology | Filgrastim | Health | Health Management | Neulasta | Neupogen | Pharmaceuticals